Wockhardt Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Wockhardt reported a sharp turnaround on a standalone basis in Q2 FY26, with profit after tax of ₹54 crore versus a loss of ₹36 crore in the year-ago quarter, driven by lower total expenses (₹356 cr vs ₹417 cr) and higher other income. Standalone revenue from operations rose modestly to ₹380 crore (₹370 cr YoY). On a consolidated basis, Q2 revenue declined about 6% YoY to ₹762 crore, but the company swung to a profit of ₹82 crore from a loss of ₹16 crore a year earlier. The board approved a ₹97 crore exceptional charge relating to the deconsolidation of its US step-down subsidiaries — Morton Grove Pharmaceuticals Inc and Wockhardt USA LLC — which filed for voluntary liquidation under Chapter 7 of the US Bankruptcy Code on July 11, 2025. The board also appointed former SBI Chairman Mr. Om Prakash Bhatt as an Additional Non-Executive Independent Director, to hold office for five years subject to shareholder approval. Operating cash flow turned strongly positive at ₹189 crore (consolidated) versus ₹32 crore in the prior year period.
Short-term: The US generics exit and one-time ₹97 cr exceptional charge have already been absorbed in H1 FY26, while the sharp profit swing on both standalone and consolidated bases is positive for earnings sentiment. Long-term shareholders should note the strategic withdrawal from the loss-making US generics business, the addition of a high-profile independent director, and a meaningful rise in long-term borrowings (consolidated borrowings rose from ₹1,211 cr to ₹1,669 cr versus March 2025), which lifts leverage even as operating cash flows improved.